More recently two vaccines against staph infection, made by nabiBiopharmaceuticals and Inhibitex (nasdaq: INHX - news - people ), failed in big trials.
The nicotine vaccine (NicVAX), currently under development by NabiBiopharmaceuticals, is a chemical derivative of nicotine that is linked to a protein that induces an immune response.